Literature DB >> 19578751

Diagnostic and prognostic potential of MIB-1 proliferation index in thyroid fine needle aspiration biopsy.

Anastasios Sofiadis1, Edneia Tani, Theodoros Foukakis, Petra Kjellman, Lambert Skoog, Anders Höög, Göran Wallin, Jan Zedenius, Catharina Larsson.   

Abstract

Fine needle aspiration biopsy (FNAB) is the preferred technique for the initial diagnostic evaluation of thyroid lesions, which nevertheless poses a diagnostic challenge for all clinicians involved. The latter necessitates the use of molecular markers on thyroid cytology. MIB-1 is a molecular marker already used in the cytological evaluation of various tumors. In this study, we assessed whether MIB-1 proliferation index adds diagnostic information to the conventional cytological analysis of thyroid nodules and prognostic information in thyroid cancers. MIB-1 index for various thyroid lesions was retrospectively reviewed in a series of 504 patients. Furthermore, the prognostic value of MIB-1 index was investigated for 183 of the patients with papillary thyroid cancer (PTC). MIB-1 index was significantly higher in anaplastic thyroid cancer (ATC) compared to other tumor types (p<0.01). No significant difference in MIB-1 index was observed between thyroid adenomas and follicular carcinomas. In PTC, MIB-1 index equal to or >4% was found to be an independent factor significantly associated with higher risk of distant metastasis and disease-related mortality (p<0.05). Conclusively, this study shows that preoperative MIB-1 index assessment in FNAB of thyroid nodules offers little diagnostic information as far as follicular tumors are concerned. In cases of PTC, though, MIB-1 may serve as a prognostic indicator of disease spreading and poor survival and hence influence the planning of the overall treatment scheme.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19578751

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

1.  Significance of AgNORs and ki-67 proliferative markers in differential diagnosis of thyroid lesions.

Authors:  Hayam A Aiad; Manar A Bashandy; Asmaa G Abdou; Ahmad A Zahran
Journal:  Pathol Oncol Res       Date:  2012-10-11       Impact factor: 3.201

2.  Prognostic significance of ki-67 labeling index in papillary thyroid carcinoma.

Authors:  Yasuhiro Ito; Akira Miyauchi; Kennichi Kakudo; Mitsuyoshi Hirokawa; Kaoru Kobayashi; Akihiro Miya
Journal:  World J Surg       Date:  2010-12       Impact factor: 3.352

3.  Prognostic factors of papillary and follicular carcinomas in Japan based on data of kuma hospital.

Authors:  Yasuhiro Ito; Akira Miyauchi
Journal:  J Thyroid Res       Date:  2011-09-29

4.  Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma.

Authors:  Andrii Dinets; Mykola Hulchiy; Anastasios Sofiadis; Mehran Ghaderi; Anders Höög; Catharina Larsson; Jan Zedenius
Journal:  Eur J Endocrinol       Date:  2012-03-28       Impact factor: 6.664

Review 5.  The diagnostic and prognostic values of Ki-67/MIB-1 expression in thyroid cancer: a meta-analysis with 6,051 cases.

Authors:  Deng-Hua Pan; Dong-Yue Wen; Yi-Huan Luo; Gang Chen; Hong Yang; Jun-Qiang Chen; Yun He
Journal:  Onco Targets Ther       Date:  2017-07-03       Impact factor: 4.147

6.  High Ki-67 index in fine needle aspiration cytology of follicular thyroid tumors is associated with increased risk of carcinoma.

Authors:  Ninni Mu; C Christofer Juhlin; Edneia Tani; Anastasios Sofiadis; Eva Reihnér; Jan Zedenius; Catharina Larsson; Inga-Lena Nilsson
Journal:  Endocrine       Date:  2018-05-23       Impact factor: 3.633

7.  Prognostic Utility of the Ki-67 Labeling Index in Follicular Thyroid Tumors: a 20-Year Experience from a Tertiary Thyroid Center.

Authors:  L Samuel Hellgren; Adam Stenman; Johan O Paulsson; Anders Höög; Catharina Larsson; Jan Zedenius; C Christofer Juhlin
Journal:  Endocr Pathol       Date:  2022-03-19       Impact factor: 4.056

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.